Literature DB >> 2939946

Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.

A E Chang, S Y Shu, T Chou, R Lafreniere, S A Rosenberg.   

Abstract

A syngeneic transplantable sarcoma induced in C57BL/6 mice, MCA 105, was used in studies to examine host suppression on the adoptive immunotherapy of established intradermal and experimentally induced pulmonary and hepatic metastases. Fresh immune splenocytes were generated from mice immunized to the MCA 105 tumor by a mixture of viable tumor cells and Corynebacterium parvum. The adoptive immunotherapy of intradermal MCA 105 tumor with immune cells required prior immunosuppression of the recipient by sublethal irradiation with 500 R or T-cell depletion. The effect of whole-body sublethal irradiation appeared to eliminate a systemic host suppression mechanism, since partialbody irradiation involving the tumor-bearing area did not permit successful immunotherapy. Host irradiation was not required to achieve successful immunotherapy of experimentally induced pulmonary or hepatic metastases. In nonirradiated recipients bearing both intradermal and pulmonary tumors, host suppression did not affect the function of transferred immune cells to induce regression of pulmonary metastases. Thus, suppression of adoptive immunotherapy appears to be relevant to tumors confined to the skin and subcutaneous tissue but not to tumor in visceral sites, such as the lung and liver.

Entities:  

Mesh:

Year:  1986        PMID: 2939946

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

2.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

3.  Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.

Authors:  Shuang Wei; Martin U Egenti; Seagal Teitz-Tennenbaum; Weiping Zou; Alfred E Chang
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

4.  Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.

Authors:  T Reissmann; R Voegeli; J Pohl; P Hilgard
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Activation of T lymphocytes for the adoptive immunotherapy of cancer.

Authors:  J J Sussman; S Shu; V K Sondak; A E Chang
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

6.  Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

Authors:  R B Cameron; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.